Effect of deoxycytidine on the metabolism and cytotoxicity of 5-aza-2'-deoxycytidine and arabinosyl 5-azacytosine in normal and leukemic human myeloid progenitor cells.

Abstract:

:The effect of deoxycytidine (dCyd) on the inhibitory effects of two antileukemic nucleoside analogs, 5-aza-2'-deoxycytidine and ara-5-aza-Cyd, toward the clonogenic growth of normal human bone marrow progenitors (CFU-GM) and leukemic blast progenitors (L-CFU) was examined. Continuous exposure of cells to 10(-6)-10(-5) M 5-aza-deoxycytidine or 10(-5)-5 x 10(-5) M ara-5-aza-Cyd in conjunction with a 10- 100-fold excess of dCyd resulted in significantly greater restoration of CFU-GM growth than L-CFU colony formation at each dose relationship. Normal bone marrow mononuclear cells exposed to 10(-3) M dCyd for 4 hr (along with 5-aza-dCyd or ara-5-aza-Cyd) exhibited intracellular deoxycytidine triphosphate (dCTP) pools 20-fold higher than their leukemic counterparts. However, this finding was not associated with enhanced analog incorporation into leukemic cell DNA. These results suggest that high concentrations of dCyd preferentially protect normal versus leukemic progenitor cells from the inhibitory actions of 5-aza-dCyd and ara-5-aza-Cyd. They also raise the possibility that this in vitro selectivity may be related to enhanced expansion of dCTP pools in normal bone marrow elements and involves factors other than differential short-term analog incorporation into DNA.

journal_name

Leukemia

journal_title

Leukemia

authors

Bhalla K,Cole J,MacLaughlin W,Arlin Z,Baker M,Graham G,Grant S

subject

Has Abstract

pub_date

1987-12-01 00:00:00

pages

814-9

issue

12

eissn

0887-6924

issn

1476-5551

journal_volume

1

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • A novel arsenical has antitumor activity toward As2O3-resistant and MRP1/ABCC1-overexpressing cell lines.

    abstract::Inorganic arsenic trioxide (As(2)O(3)) is a highly effective treatment for acute promyelocytic leukemia (APL). However, other cancers do not respond well to this form of arsenic at clinically achievable doses. We tested a novel arsenical, S-dimethylarsino-glutathione (darinaparsin) for efficacy in various malignancies...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2008.194

    authors: Diaz Z,Mann KK,Marcoux S,Kourelis M,Colombo M,Komarnitsky PB,Miller WH Jr

    更新日期:2008-10-01 00:00:00

  • Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT.

    abstract::Allogeneic haemopoietic cell transplant (allo-HCT) may be curative in acute myeloid leukaemia (AML) in second complete remission (CR2) but the impact of reduced intensity (RIC) versus myeloablative conditioning (MAC) is uncertain. The Acute Leukaemia Working Party of the European Society for Blood and Bone Marrow Tran...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-019-0527-4

    authors: Gilleece MH,Labopin M,Savani BN,Yakoub-Agha I,Socié G,Gedde-Dahl T,Blaise D,Byrne JL,Craddock C,Cornelissen JJ,Arcese W,Forcade E,Crawley C,Polge E,Mohty M,Nagler A

    更新日期:2020-01-01 00:00:00

  • The percentage of myeloperoxidase-positive blast cells is a strong independent prognostic factor in acute myeloid leukemia, even in the patients with normal karyotype.

    abstract::To examine whether the percentage of myeloperoxidase (MPO)-positive blast cells is useful as a prognostic factor for acute myeloid leukemia (AML), cytochemical analysis of MPO was performed in 491 patients who were registered to the Japan Adult Leukemia Study Group-AML92 study. Patients were divided into two using the...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403010

    authors: Matsuo T,Kuriyama K,Miyazaki Y,Yoshida S,Tomonaga M,Emi N,Kobayashi T,Miyawaki S,Matsushima T,Shinagawa K,Honda S,Ohno R,Japan Adult Leukemia Study Group.

    更新日期:2003-08-01 00:00:00

  • Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay.

    abstract::The AML1/ETO fusion transcript can be detected by reverse transcription polymerase chain reaction (RT-PCR) in patients with t(8;21)-associated acute myeloid leukemia (AML) in long-term complete remission (CR). Quantitation of the amount of the fusion transcript during CR may therefore be more predictive of cure or rel...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401128

    authors: Marcucci G,Livak KJ,Bi W,Strout MP,Bloomfield CD,Caligiuri MA

    更新日期:1998-09-01 00:00:00

  • Criteria for the definition of Epstein-Barr virus association in Hodgkin's disease.

    abstract::There is a clear association between the Epstein-Barr virus (EBV) and Hodgkin's disease (HD). EBV is not, however, detectable within the affected tissues of all cases. The proportion of positive cases varies from 15-79% depending on the assay used to detect EBV. The techniques utilised vary not only in sensitivity but...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Armstrong AA,Weiss LM,Gallagher A,Jones DB,Krajewski AS,Angus B,Brown G,Jack AS,Wilkins BS,Onions DE

    更新日期:1992-09-01 00:00:00

  • Acute myeloblastic leukemia with t(8;21) following Philadelphia positive acute lymphoblastic leukemia.

    abstract::A patient with Philadelphia positive (Ph'+) acute lymphoblastic leukemia (ALL), in remission for over 4 years, developed an acute myeloblastic leukemia (AML), M2-type. During the second disease, the blast cells displayed a typical t(8;21)(q22;q22) translocation, in the absence of the Ph' chromosome. This is the first ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: De Cuia MR,Alimena G,Gastaldi R,Spiriti MA,Giona F,Mancini M,Mandelli F

    更新日期:1989-04-01 00:00:00

  • Evidence against a direct cytotoxic effect of alpha interferon and zidovudine in HTLV-I associated adult T cell leukemia/lymphoma.

    abstract::The combination of the anti-viral agents, zidovudine (AZT) and interferon-alpha (IFN), is a potent treatment of HTLV-I-associated adult T cell leukemia/lymphoma (ATL). In this study we investigate the possible mechanism of action of this combination by examining several cellular parameters including cell proliferation...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401742

    authors: Bazarbachi A,Nasr R,El-Sabban ME,Mahé A,Mahieux R,Gessain A,Darwiche N,Dbaibo G,Kersual J,Zermati Y,Dianoux L,Chelbi-Alix MK,de Thé H,Hermine O

    更新日期:2000-04-01 00:00:00

  • Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma.

    abstract::Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)-a subtype of Hodgkin lymphoma (HL)-is characterized by a low content of tumor cells, the lymphocyte predominant (LP) cells. Transformation into diffuse large B-cell lymphoma (DLBCL) occurs in about 10% of patients. We performed whole-genome mutation analysis of t...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2015.328

    authors: Hartmann S,Schuhmacher B,Rausch T,Fuller L,Döring C,Weniger M,Lollies A,Weiser C,Thurner L,Rengstl B,Brunnberg U,Vornanen M,Pfreundschuh M,Benes V,Küppers R,Newrzela S,Hansmann ML

    更新日期:2016-04-01 00:00:00

  • A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies.

    abstract::To guide development of new clinical strategies, a review of recent investigations in the pathobiology of MDS was performed. Articles were identified through a Medline search. Studies, including reviews, are cited in the references. A multistep pathogenesis is proposed. (1) Targeted injury or mutation within hemopoiet...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/sj.leu.2401618

    authors: Rosenfeld C,List A

    更新日期:2000-01-01 00:00:00

  • Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma.

    abstract::Osteolytic bone disease in multiple myeloma (MM) is caused by enhanced osteoclast (OCL) activation and inhibition of osteoblast function. Lenalidomide and bortezomib have shown promising response rates in relapsed and newly diagnosed MM, and bortezomib has recently been reported to inhibit OCLs. We here investigated t...

    journal_title:Leukemia

    pub_type: 杂志文章,随机对照试验

    doi:10.1038/leu.2008.174

    authors: Breitkreutz I,Raab MS,Vallet S,Hideshima T,Raje N,Mitsiades C,Chauhan D,Okawa Y,Munshi NC,Richardson PG,Anderson KC

    更新日期:2008-10-01 00:00:00

  • LRPAP1 is a frequent proliferation-inducing antigen of BCRs of mantle cell lymphomas and can be used for specific therapeutic targeting.

    abstract::The predominant usage of VH4-34 and V3-21 and reports of stereotyped CDR3s suggest a shared antigenic target of B-cell receptors (BCR) from mantle cell lymphomas (MCL). To identify the target antigens of MCL-BCRs, BCRs from 21 patients and seven MCL cell lines were recombinantly expressed and used for antigen screenin...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-018-0182-1

    authors: Thurner L,Hartmann S,Fadle N,Kemele M,Bock T,Bewarder M,Regitz E,Neumann F,Nimmesgern A,von Müller L,Pott C,Kim YJ,Bohle RM,Wasik M,Schuster SJ,Hansmann ML,Preuss KD,Pfreundschuh M

    更新日期:2019-01-01 00:00:00

  • BCR/ABL-mediated downregulation of genes implicated in cell adhesion and motility leads to impaired migration toward CCR7 ligands CCL19 and CCL21 in primary BCR/ABL-positive cells.

    abstract::The mechanism underlying p210(BCR/ABL) oncoprotein-mediated transformation in chronic myelogenous leukemia (CML) is not fully understood. We hypothesized that p210(BCR/ABL) suppresses expression of genes which may explain at least some of the pathogenetic features of CML. A subtractive cDNA library was created between...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403626

    authors: Jongen-Lavrencic M,Salesse S,Delwel R,Verfaillie CM

    更新日期:2005-03-01 00:00:00

  • Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.

    abstract::Most modern treatment protocols for acute lymphoblastic leukaemia (ALL) include the analysis of minimal residual disease (MRD). To ensure comparable MRD results between different MRD-polymerase chain reaction (PCR) laboratories, standardization and quality control are essential. The European Study Group on MRD detecti...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/sj.leu.2404586

    authors: van der Velden VH,Cazzaniga G,Schrauder A,Hancock J,Bader P,Panzer-Grumayer ER,Flohr T,Sutton R,Cave H,Madsen HO,Cayuela JM,Trka J,Eckert C,Foroni L,Zur Stadt U,Beldjord K,Raff T,van der Schoot CE,van Dongen JJ,Euro

    更新日期:2007-04-01 00:00:00

  • Establishment of multipotential and antigen presenting cell lines derived from myeloid leukemias in GM-CSF transgenic mice.

    abstract::In this study neonatal mice expressing a GM-CSF transgene (GMT mice), and their normal littermate controls, were infected with Moloney murine leukemia virus (MoMLV) to examine in vivo tumorigenesis. By 200 days, all of the GMT mice had died whereas median survival had not been reached in the littermates (P < 0.0003). ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400614

    authors: Rasko JE,Metcalf D,Alexander B,Strasser A,Begley CG

    更新日期:1997-05-01 00:00:00

  • Amplification and sequencing of genomic breakpoints located within the M-bcr region by Vectorette-mediated polymerase chain reaction.

    abstract::The polymerase chain reaction (PCR) cannot be used to amplify the breakpoint in the chimaeric BCR-ABL gene in CML and acute leukaemias due to the large variation in the sites of breakpoint in the BCR gene (within a 5.8 kb region) and in the ABL gene (within a 150 kb region). The disease state is usually monitored usin...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Mills KI,Sproul AM,Ogilvie D,Elvin P,Leibowitz D,Burnett AK

    更新日期:1992-05-01 00:00:00

  • Molecular characterization of jumping translocations reveals spatial and temporal breakpoint heterogeneity.

    abstract::Jumping translocations (JT) are characterized by the relocalization of the same part of a donor to several recipient chromosomes. Although JT occasionally are constitutional, most are associated with hematologic malignancies. In such cases, JT usually arise during disease progression and are associated with poor progn...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401108

    authors: Andreasson P,Höglund M,Jonson T,Békàssy A,Mitelman F,Johansson B

    更新日期:1998-09-01 00:00:00

  • Analysis of mutations in the GM-CSF receptor alpha coding sequence in patients with acute myeloid leukaemia and haematologically normal individuals by RT-PCR-SSCP.

    abstract::Mutations of signal transducing molecules such as Ras have been shown to confer a growth advantage in leukaemic blasts and contribute to the pathogenesis of the disease. Alterations of signal transducing molecules other than Ras may play a role in leukaemogenesis. Knowledge of such mutations could also further our und...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Wagner HM,Gale RE,Freeburn RW,Devereux S,Linch DC

    更新日期:1994-09-01 00:00:00

  • Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers.

    abstract::Sequential analysis of chimerism after allogeneic blood stem cell transplantation (BSCT) has been shown to be predictive for graft failure and relapse. We have explored the impact of a novel approach for the quantitative determination of chimerism using a commercial PCR assay with multiplex amplification of nine STR-l...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401953

    authors: Thiede C,Bornhäuser M,Oelschlägel U,Brendel C,Leo R,Daxberger H,Mohr B,Florek M,Kroschinsky F,Geissler G,Naumann R,Ritter M,Prange-Krex G,Lion T,Neubauer A,Ehninger G

    更新日期:2001-02-01 00:00:00

  • Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells.

    abstract::Natural killer T (NKT) cells with an invariant T-cell receptor for alpha-galactosylceramide (alphaGalCer) that is presented by CD1d have been reported to be cytotoxic for myelomonocytic leukemia cells. However, the necessity for leukemia cell CD1d expression, the role of alphaGalCer, and the cytotoxic mechanisms have ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402943

    authors: Metelitsa LS,Weinberg KI,Emanuel PD,Seeger RC

    更新日期:2003-06-01 00:00:00

  • Transformation of murine pre-B-lymphocytes by v-erb-B: progression to growth factor independence and tumorigenicity.

    abstract::v-erb-B is the principal transforming gene of avian erythroblastosis virus, a replication defective retrovirus that transforms erythroid and fibroblast cells in vitro and causes erythroleukemia and fibrosarcoma in vivo. We have used a recombinant murine retrovirus, based on the truncated genome of Moloney murine leuke...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Miller M,Kennewell A,Symonds G

    更新日期:1992-01-01 00:00:00

  • Validity of the in vitro system as a correlate of the in vivo model of RadLV lymphomagnesis.

    abstract::Adult BL/6 mice are highly sensitive to lymphomagnesis by the radiation leukemia virus variant A-RadLV (80-100% T-cell lymphoma incidence after a latency of 70-110 days). This study shows that the in vivo elimination of T-cell subsets (including suppressor and cytotoxic T-cells) achieved by the repeated administration...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Haran-Ghera N,Peled A

    更新日期:1991-06-01 00:00:00

  • High level of cannabinoid receptor 1, absence of regulator of G protein signalling 13 and differential expression of Cyclin D1 in mantle cell lymphoma.

    abstract::Mantle cell lymphoma (MCL) is a moderately aggressive B-cell lymphoma that responds poorly to currently used therapeutic protocols. In order to identify tumour characteristics that improve the understanding of biology of MCL, analysis of oligonucleotide microarrays were used to define specific gene expression profiles...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403057

    authors: Islam TC,Asplund AC,Lindvall JM,Nygren L,Liden J,Kimby E,Christensson B,Smith CI,Sander B

    更新日期:2003-09-01 00:00:00

  • The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes.

    abstract::The Wilms' tumor gene, WT1, is a tumor marker for leukemic blast cells. The WT1 expression levels were examined for 57 patients with myelodysplastic syndromes (MDS) (refractory anemia (RA), 35; RA with excess of blasts (RAEB) 14; RAEB in transformation (RAEB-t), six; and MDS with fibrosis, two) and 12 patients with ac...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401341

    authors: Tamaki H,Ogawa H,Ohyashiki K,Ohyashiki JH,Iwama H,Inoue K,Soma T,Oka Y,Tatekawa T,Oji Y,Tsuboi A,Kim EH,Kawakami M,Fuchigami K,Tomonaga M,Toyama K,Aozasa K,Kishimoto T,Sugiyama H

    更新日期:1999-03-01 00:00:00

  • Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia.

    abstract::We analyzed the long-term outcome of 1011 patients treated in five successive clinical trials (Total Therapy Studies 11, 12, 13A, 13B, and 14) between 1984 and 1999. The event-free survival improved significantly (P=0.003) from the first two trials conducted in the 1980s to the three more recent trials conducted in th...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章

    doi:10.1038/leu.2009.252

    authors: Pui CH,Pei D,Sandlund JT,Ribeiro RC,Rubnitz JE,Raimondi SC,Onciu M,Campana D,Kun LE,Jeha S,Cheng C,Howard SC,Metzger ML,Bhojwani D,Downing JR,Evans WE,Relling MV

    更新日期:2010-02-01 00:00:00

  • Histone deacetylase inhibitors interrupt HSP90•RASGRP1 and HSP90•CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cells.

    abstract::Histone deacetylase (HDAC) inhibitors, which are approved for the treatment of cutaneous T-cell lymphoma and multiple myeloma, are undergoing evaluation in other lymphoid neoplasms. How they kill susceptible cells is incompletely understood. Here, we show that trichostatin A, romidepsin and panobinostat induce apoptos...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2016.357

    authors: Ding H,Peterson KL,Correia C,Koh B,Schneider PA,Nowakowski GS,Kaufmann SH

    更新日期:2017-07-01 00:00:00

  • Mutational and expression analysis of the chromosome 12p candidate tumor suppressor genes in pre-B acute lymphoblastic leukemia.

    abstract::Allelic losses on chromosome 12p12-13 are associated with childhood acute lymphoblastic leukemia (ALL) and several solid neoplasias, suggesting the presence of a tumor suppressor locus. The recent construction of a transcription map of this locus has enabled the identification of eight genes, of which five were previo...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403441

    authors: Montpetit A,Larose J,Boily G,Langlois S,Trudel N,Sinnett D

    更新日期:2004-09-01 00:00:00

  • Presenting features and treatment outcome of adolescents with acute lymphoblastic leukemia.

    abstract::Adolescents had lower rates of remission induction and shorter event-free survival than younger children in this study of consecutively treated patients with acute lymphoblastic leukemia (ALL). When compared to the younger patients (ages 1-9 years; n = 995), adolescents (ages 10-21 years; n = 338) were significantly m...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Santana VM,Dodge RK,Crist WM,Rivera GK,Look AT,Behm FG,Raimondi SC,Pui CH

    更新日期:1990-02-01 00:00:00

  • DNA microarrays for comparison of gene expression profiles between diagnosis and relapse in precursor-B acute lymphoblastic leukemia: choice of technique and purification influence the identification of potential diagnostic markers.

    abstract::Microarrays for gene expression profiling are rapidly becoming important research tools for the identification of novel markers, for example, for novel classification of leukemias and lymphomas. Here, we review the considerations and infrastructure for microarray experiments. These considerations are illustrated via a...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402974

    authors: Staal FJ,van der Burg M,Wessels LF,Barendregt BH,Baert MR,van den Burg CM,van Huffel C,Langerak AW,van der Velden VH,Reinders MJ,van Dongen JJ

    更新日期:2003-07-01 00:00:00

  • Characterisation of non-concordance in the T-cell receptor gamma chain genes at presentation and clinical relapse in acute lymphoblastic leukemia.

    abstract::We have analysed the structure of the T-cell receptor gamma chain (TCRG) genes in a panel of biopsies taken from 24 patients with acute lymphoblastic leukemia (ALL) (13 cALL, one pre-B ALL, two null ALL and eight T-ALL) at presentation and at clinical relapse. In the majority of cases (18/24) the structure of these ge...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Taylor JJ,Rowe D,Kylefjord H,Chessells J,Katz F,Proctor SJ,Middleton PG

    更新日期:1994-01-01 00:00:00

  • Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity.

    abstract::c-MYC (hereafter MYC) overexpression has been recognized in aggressive B-cell lymphomas and linked to adverse prognosis. MYC activation results in widespread repression of micro-RNA (miRNA) expression and associated with lymphoma aggressive progression. Our recent study identified a MYC-miRNA-EZH2 feed-forward loop li...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2013.94

    authors: Zhao X,Lwin T,Zhang X,Huang A,Wang J,Marquez VE,Chen-Kiang S,Dalton WS,Sotomayor E,Tao J

    更新日期:2013-12-01 00:00:00